SABCS 2022: Second-Line Trastuzumab Deruxtecan Improves Overall Survival in Patients With Metastatic Breast Cancer
Benefit for overall and progression-free survival maintained with longer treatment duration, along with a manageable safety profile
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.